PK and Safety of BR1017-1 vs Co-administration of BR1017-1A and BR1017-1B in Healthy Volunteers

Phase 1, randomised, open-label trial of fimasartan, atorvastatin and ezetimibe in essential hypertension and hypercholesterolemia (2 arms), sponsored by Boryung. Primary endpoints: Area Under the Curve over the dosing interval (tau) and Maximum Plasma Concentration. Started Dec 2023; status: completed.